'Tb drugs' diaporamas de présentation

Progress Towards 3 x 5 Uganda 2003-2005

Progress Towards 3 x 5 Uganda 2003-2005. Geoffrey Taylor Division of Infectious Diseases University of Alberta. DART : triple NRTI ( AZT/3TC/TDF) randomized to lab vs clinical monitoring and to continuous vs interupted therapy 54% <50 copies @ 24 wks.

582 views • 50 slides

Tuberculosis Update

Tuberculosis Update. Jacqueline Peterson Tulsky, MD Pacific AETC Associate Clinical Professor, UCSF San Francisco General Hospital Positive Health Program. March 2004. Summary of Points. 1. Latent Tuberculosis Infection (LTBI) Rifampin + Pyrazinamide (PZA) for 60 doses

688 views • 46 slides

TUBERCULOSIS IN THE AGE OF HIV

TUBERCULOSIS IN THE AGE OF HIV. Dr. Terry Baker Physician National Chest Hospital. THE PROBLEM. Global epidemic of HIV infection. HIV- infected persons highly susceptible to M. tuberculosis disease. Impact of HIV epidemic and TB greatest in the developing world.

592 views • 33 slides

389 views • 29 slides

Treatment Studies in the Pipeline

Treatment Studies in the Pipeline. IMPAACT HIV Treatment Scientific Committee Update IMPAACT Community and Science Theodore Ruel MD 11 June 2019. Proposals and Protocols in Development. IMPAACT 2026 PK of ARVs, Anti-TB Meds, and Hormonal Contraceptives During Pregnancy and Postpartum.

485 views • 28 slides

Charles Flexner, MD Johns Hopkins University

PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection. Charles Flexner, MD Johns Hopkins University. What have we learned about TB pharmacology? Drug concentrations matter!. Association of rifabutin AUC with TBC treatment response.

379 views • 27 slides

Overview of 2000 Survey of TB Drug Supply Experiences in Low- and Middle-Income WHO Member States

Overview of 2000 Survey of TB Drug Supply Experiences in Low- and Middle-Income WHO Member States Diana Weil Senior Public Health Specialist World Bank/United States. Appreciation.

334 views • 24 slides

Dollars and disease Marrying social, economic and disease dynamic perspectives for public health

Dollars and disease Marrying social, economic and disease dynamic perspectives for public health. Nim Arinaminpathy Imperial College London. Roles of transmission models in public health. Supporting healthcare delivery. Informing decision-making. Basic science: contributing

276 views • 19 slides

QUAN 1

Vertical versus Decentralized TB Pharmaceutical Management. QUAN 1. Preliminary Considerations. Note : it is hard to distinguish which of the following pros & cons are truly different for TB drugs versus other essential medicines. .

391 views • 18 slides

Tuberculosis quick facts Illustrated through drawings from children across the Region

254 views • 14 slides

Tuberculosis Research Funding

197 views • 13 slides

Background

Assessment Survey of TB Drug Management in Cambodia Uchiyama Y, Chay S, Kousoum M, Leng C, Kien S, Nou C, Chhom C (CENAT/JICA National TB Control Project, Cambodia). Background

207 views • 12 slides

TB Track Evidence-based recommendations

443 views • 11 slides

Global TB Drug Facility

143 views • 11 slides

Three key messages on tuberculosis control

Three key messages on tuberculosis control. World Tuberculosis Day 2010. ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2010. Message 1 The treatment success rate in the EU/EEA is too low to meet global targets.

252 views • 11 slides

Background 1

195 views • 11 slides

TB Track Evidence-based recommendations

225 views • 11 slides

Tuberculosis

318 views • 8 slides

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Ben

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin. Group 1 Countries. Uganda Democratic Republic of Congo Congo Brazzaville Nigeria Benin Republic. Policy and Legal Framework: Strengths.

514 views • 7 slides

150 views • 1 slides